Good day, 360!
Say goodbye to trading indecision with Jason Bond LIVE. All of Jason’s services plus a Psychology bonus. Get direct access to a Wall St legend with live streams and real time trade alerts here.
FOCUS LIST🔎
WW – Up over 50% in the pre-market after yesterday announcing it would offer a weight loss drug with similar ingredients to Ozempic
CLSD – Up over 29% pre after announcing positive topline results from ODYSSEY phase 2b trial of Suprachoroidal CLS-AX in Wet AMD achieving all primary and secondary outcomes
RIME – Up over 24% in pre after SemiCab wins major new contract with $10 billion Indian consumer packaged goods company for new pilot in India
*together with 1440 Media
All your news. None of the bias.
Be the smartest person in the room by reading 1440! Dive into 1440, where 3.5 million readers find their daily, fact-based news fix. We navigate through 100+ sources to deliver a comprehensive roundup from every corner of the internet – politics, global events, business, and culture, all in a quick, 5-minute newsletter. It’s completely free and devoid of bias or political influence, ensuring you get the facts straight.
HOTLIST🔥
WW – Up over 50% in the pre-market after yesterday announcing it would offer a weight loss drug with similar ingredients to Ozempic
WW International Inc. (WW) provides weight management products and services worldwide. The company was formerly known as Weight Watchers International, Inc.
Yesterday, the company announced the addition of compounded semaglutide into its offering. Semaglutide is the same ingredient used in blockbuster weight loss drug Ozempic. WW stated that the new offering will start at $129.
WW traded up over 50% in the pre-market this morning, after closing up over 46% yesterday in reaction to the news.
The first target for bulls is the pre-market high at $1.86.
Beyond that, $2, $2.30, $2.70, $2.90, $3 and $3.50 come into play.
Below $1.86, targets to the downside are $1.60, $1.55, $1.50, $1.40, $1.30, $1.20 and then a gap fill at $1.16.
CLSD – Up over 29% pre after announcing positive topline results from ODYSSEY phase 2b trial of Suprachoroidal CLS-AX in Wet AMD achieving all primary and secondary outcomes
Clearside Biomedical Inc. (CLSD) is a biopharmaceutical company that focuses on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
In the pre-market this morning, the company announced that the ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD) achieved both its primary and secondary outcomes.
Highlights Include:
– Maintained Stable Visual Acuity and Anatomical Control Over 9 Months
– Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events
– 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months
– Reduced Treatment Burden by 84% Over 6 Months
The stock traded up over 29% in the pre-market in reaction to the results.
The $1.82 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $2, $2.09 and then the pre-market high at $2.54. Above that, $2.80 comes into play.
Below $1.82, targets to the downside are $1.70 and then a gap fill at $1.48.
ALL of Jason’s Trades
Order flow, LIVE! Portfolio, LIVE! Jason, LIVE!
October’s Trading Live
Results not typical. Trading is hard. Nothing is guaranteed.
RIME – Up over 24% in pre after SemiCab wins major new contract with $10 billion Indian consumer packaged goods company for new pilot in India
Algorhythm Holdings Inc. (RIME) is an AI-driven technology and consumer electronics holding company.
In the pre-market this morning, the company announced the signing of a new master service agreement with a leading Mumbai-based multinational consumer goods company specializing in health, beauty, wellness, and healthy packaged foods.
Under the agreement, Algorhythm’s subsidiary, SemiCab Holdings, LLC, will provide enterprise-level shipping services through its AI-powered software platform, designed to reduce service costs, improve delivery accuracy, and eliminate empty miles. The contract, set to commence in mid-October 2024, will cover several major metropolitan markets across India.
The stock traded up over 24% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $0.7451.
Beyond that, targets to the upside are $0.7810, $0.85, $0.9090, $1, $1.15 and then $1.30.
Below $0.7451, targets to the downside are $0.66, $0.62, $0.55 and then a gap fill at $0.5390.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
